Stoke Therapeutics (STOK) News Today

Stoke Therapeutics, Inc. (NASDAQ:STOK) saw mixed signals today as analysts adjusted earnings forecasts, insiders sold shares and trading volumes spiked.

• Positive Sentiment: Leerink Partnrs raised its FY2027 loss estimate to ($2.35) per share from ($3.10), signaling a smaller-than-expected decline in earnings.
• Positive Sentiment: Stoke Therapeutics received a consensus “Buy” rating from ten analysts, reflecting strong confidence among Wall Street firms. Consensus Buy Rating
• Neutral Sentiment: Short interest remained at zero shares with a days-to-cover ratio of 0.0, indicating minimal bearish positioning.
• Neutral Sentiment: The stock experienced an 11.7% surge on higher-than-average volume, though recent downward revisions to estimates may curb further gains. Surge Analysis
• Neutral Sentiment: Trading volume spiked to unusual levels, but there was no specific catalyst identified. Volume Spike
• Negative Sentiment: Leerink Partnrs cut its FY2028 EPS estimate sharply to ($2.80) from ($1.40), deepening the projected loss outlook.
• Negative Sentiment: Leerink Partnrs lowered its FY2029 forecast to a $0.40 loss per share from prior expectations of $0.30 in earnings.
• Negative Sentiment: Weiss Ratings reaffirmed a “Sell (D+)” rating, underscoring persistent skepticism among some analysts. Weiss Ratings Sell Rating
• Negative Sentiment: Stoke’s general counsel sold 10,000 shares at an average price of $25.07, reducing insider holdings and potentially signaling less confidence at the executive level. Insider Sale

Overall, mixed analyst revisions and a reiterated sell rating have weighed on STOK, partially offset by a consensus buy stance and an improved FY2027 outlook. Investors should watch upcoming clinical milestones and guidance for clearer direction.